

May 29, 2019



## Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in June

Norwood, MA, May 29, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at two upcoming investor conferences in June.

The following are the details for the conferences:

Event: Jefferies 2019 Global Healthcare Conference

Date: Tuesday, June 4, 2019

Time: 2:30 p.m. Eastern Time

Location: Grand Hyatt, New York, NY

Event: Live Fireside Chat at JMP Securities Life Sciences Conference

Date: Thursday, June 20, 2019

Time: 10:30 a.m. Eastern Time

Location: The St. Regis, New York, NY

Live audio webcast of both the presentations will be accessible on the [Events](#) page of the [Investors](#) section of the Corbus website, [www.corbuspharma.com](http://www.corbuspharma.com) and will be archived for 90 days following the event.

### About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of endocannabinoid system-targeting synthetic drug candidates. The Company's lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Corbus is also developing a pipeline of drug candidates from more than 600 novel

compounds targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist. Potential indications for CRB-4001 include NASH, among others. Corbus plans to start a Phase 1 study of CRB-4001 in 2019, intended to be followed by a National Institutes of Health (NIH)-funded proof-of-concept Phase 2 study.

For more information, please visit [www.CorbusPharma.com](http://www.CorbusPharma.com) and connect with the Company on [Twitter](#), [LinkedIn](#), and [Facebook](#).

### **Forward-Looking Statements**

Statements in this press release that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements about Corbus' expectations regarding the completion, timing and size of its public offering and the anticipated use of proceeds therefrom. Words such as "believe," "anticipate," "plan," "expect," "intend," "may," "goal," "potential" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with market conditions as well as risks and uncertainties associated with Corbus' business and finances in general, including the risks and uncertainties in the section captioned "Risk Factors" in the prospectus supplement related to the public offering that was filed with the SEC and the Company's most recently filed Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Corbus undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

### **Corbus Pharmaceuticals Contacts:**

Ted Jenkins, Senior Director, Investor Relations and Corporate Communications

Phone: +1 (617) 415-7745

Email: [ir@corbuspharma.com](mailto:ir@corbuspharma.com)

Lindsey Smith, Associate Director, Investor Relations and Corporate Communications

Phone: +1 (617) 415-7749

Email: [mediainfo@corbuspharma.com](mailto:mediainfo@corbuspharma.com)

Jenene Thomas

Jenene Thomas Communications, LLC

Phone: +1 (833) 475-8247

Email: [crbp@jtcir.com](mailto:crbp@jtcir.com)



Source: Corbus Pharmaceuticals Holdings, Inc.